Combination of carrageenan and a neuraminidase inhibitor as superior treatment for influenza A

Benjamin Reutterer1, Marielle König-Schuster1, Christiane Koller1, Romana Stückler2, Elisabeth Dobias1, Philipp Graf1, Peter Stäheli2, Hermann Unger1, Eva Frieschl-Grassauer1 and Andreas Grassauer3

1Marinomed, Biotechnologie GmbH, Vienna, Austria, 2Universitätsklinikum Freiburg, Department of Virology, Freiburg, Germany, 3Laboratory of Tropical Veterinary Medicine, Veterinary University Vienna, Vienna, Austria

Introduction:
The 2009 flu pandemic and the appearance of neuraminidase-inhibitor resistant H1N1 influenza strains highlights the need for treatment alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. Consequently, we tested a novel combination of carrageenans together with the neuraminidase inhibitor Zanamivir in in vitro and in vivo infection experiments. This combination showed a high protection level against novel H1N1 influenza.

Results:
Treatment of mice infected with a lethal dose of influenza A PR/8/34 (H1N1) or A/HH/01/2009 (H1N1) virus resulted in a strong protection of infected animals.

Conclusions:
Novel treatment options for influenza are desperately needed. Based on these encouraging results in animals we suggest testing a nasal spray containing carrageenans in combination with neuraminidase inhibitors in a clinical trial for prevention or treatment of influenza A in humans.

**In vitro effect of Carrageenan plus Zanamivir after infection with influenza A PR/8/34 (H1N1)**

![In vitro effect of Carrageenan plus Zanamivir after infection with influenza A PR/8/34 (H1N1)](image1)

**In vitro effect of Carrageenan plus Zanamivir after infection with influenza A/HH/01/2009 (H1N1)**

![In vitro effect of Carrageenan plus Zanamivir after infection with influenza A/HH/01/2009 (H1N1)](image2)

**Methods:**
For infection experiments influenza A PR/8/34 (H1N1) and influenza A/HH/01/2009 (H1N1) viruses were used. Influenza A/Hansa Hamburg/01/2009 (A/HH/01/2009) (H1N1) was kindly provided by the group of P. Stäheli2. Plaque reduction assays were performed with Madine Darby Canine Kidney cells (MDCK). Cells were infected with an MOI of 0.01. In vivo infection experiments were performed using C57Bl/6 mice infected intranasally, following FELASA guidelines, and survival was monitored over a 14 day period. Mice received 6.3x10^5 PFU per animal for H1N1 PR/8/34 and 2.3x10^6 PFU for novel H1N1 HH09, respectively. Animals were monitored and treated twice daily. Treatment consisted of a preparation containing carrageenans (isolated from red seaweed) in combination with Zanamivir or Zanamivir alone. Statistics were performed using graph pad prism software.

**Discussion:**
We have already demonstrated the antiviral efficacy of carrageenan in infections with influenza A H1N1 PR/8/34 previously1. The present study shows that the combination of carrageenans with a neuraminidase inhibitor leads to superior protection of cells and mice compared with neuraminidase inhibitor treatment alone. Intranasal application delivers systemic levels of Zanamivir in sera of animals (data not shown). The combination of carrageenans and Zanamivir protects against infection with novel influenza A in vitro and in vivo. Taken together we propose a nasal spray containing carrageenans and Zanamivir as a novel treatment alternative for influenza A infections.

References:

Contact: benjamin.reutterer@marinomed.com